RT Journal Article
T1 Modulation of Autophagy by Sorafenib: Effects on Treatment Response.
A1 Prieto-Domínguez, Nestor
A1 Ordóñez, Raquel
A1 Fernández, Anna
A1 García-Palomo, Andres
A1 Muntané, Jordi
A1 González-Gallego, Javier
A1 Mauriz, José L
K1 Autophagy
K1 Cancer therapeutic
K1 Dug resistance
K1 Hepatocellular carcinoma
K1 Sorafenib
K1 Proteínas quinasas activadas por AMP
K1 Carcinoma hepatocelular
K1 Supervivencia celular
K1 Neoplasias hepáticas
K1 Células mieloides
K1 Compuestos de fenilurea
AB The multikinase inhibitor sorafenib is, at present, the only drug approved for the treatment of hepatocellular carcinoma (HCC), one of the most lethal types of cancer worldwide. However, the increase in the number of sorafenib tumor resistant cells reduces efficiency. A better knowledge of the intracellular mechanism of the drug leading to reduced cell survival could help to improve the benefits of sorafenib therapy. Autophagy is a bulk cellular degradation process activated in a broad range of stress situations, which allows cells to degrade misfolded proteins or dysfunctional organelles. This cellular route can induce survival or death, depending on cell status and media signals. Sorafenib, alone or in combination with other drugs is able to induce autophagy, but cell response to the drug depends on the complex integrative crosstalk of different intracellular signals. In cancerous cells, autophagy can be regulated by different cellular pathways (Akt-related mammalian target of rapamycin (mTOR) inhibition, 5' AMP-activated protein kinase (AMPK) induction, dissociation of B-cell lymphoma 2 (Bcl-2) family proteins from Beclin-1), or effects of some miRNAs. Inhibition of mTOR signaling by sorafenib and diminished interaction between Beclin-1 and myeloid cell leukemia 1 (Mcl-1) have been related to induction of autophagy in HCC. Furthermore, changes in some miRNAs, such as miR-30α, are able to modulate autophagy and modify sensitivity in sorafenib-resistant cells. However, although AMPK phosphorylation by sorafenib seems to play a role in the antiproliferative action of the drug, it does not relate with modulation of autophagy. In this review, we present an updated overview of the effects of sorafenib on autophagy and its related activation pathways, analyzing in detail the involvement of autophagy on sorafenib sensitivity and resistance.
PB Frontiers Media
YR 2016
FD 2016-06-08
LK http://hdl.handle.net/10668/2535
UL http://hdl.handle.net/10668/2535
LA en
NO Prieto-Domínguez N, Ordóñez R, Fernández A, García-Palomo A, Muntané J, González-Gallego J, et al. Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Front Pharmacol. 2016; 7:151
NO Journal Article; Review;
DS RISalud
RD Jul 30, 2025